{"filing":{"accession_number":"0001104659-26-074915","cik":"0001526119","ticker":"VSTM","company_name":"Verastem, Inc.","form":"8-K","filing_date":"2026-06-17","report_date":null,"primary_document":"tm2618108d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1526119/000110465926074915/tm2618108d1_8k.htm"},"events":[{"id":11467,"run_id":10066,"accession_number":"0001104659-26-074915","anchor_item_number":"8.01","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"summary":"Verastem announced positive updated results from the RAMP 205 Phase 1b/2a clinical trial evaluating avutometinib plus defactinib in combination with chemotherapy for metastatic pancreatic cancer, with an 86% overall survival rate at 6 months, 68% progression-free survival rate, and 52% objective response rate. The company also announced initiation of dosing in the TARGET-D 201 Phase 2 registration-directed trial for VS-7375.","company_name":"Verastem, Inc.","ticker":"VSTM","filing_date":"2026-06-17","form":"8-K","submitted_at":null,"items":[{"id":8063,"accession_number":"0001104659-26-074915","item_number":"7.01","item_title":"Regulation FD Disclosure","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.45,"reasoning":"The disclosure announces \"positive updated results\" from the RAMP 205 clinical trial evaluating avutometinib plus defactinib in combination with chemotherapy for metastatic pancreatic cancer. While this is a clinical trial result rather than financial earnings, it is material to a biopharmaceutical company's valuation and would significantly affect investor assessment of pipeline value and regulatory prospects. However, the taxonomy's \"earnings_release\" category is narrowly defined as \"quarterly or annual financial results,\" which this is not—it is a clinical milestone. This disclosure may be better classified as \"other_material\" since it represents a material clinical development event that does not fit the specific categories provided.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-17T12:53:14.578943+00:00","company_name":"","ticker":null,"filing_date":""},{"id":8064,"accession_number":"0001104659-26-074915","item_number":"8.01","item_title":"Other Events","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"The disclosure announces positive updated clinical trial results from the RAMP 205 Phase 1b/2a trial (86% overall survival rate at 6 months, 68% progression-free survival rate, 52% objective response rate) and the initiation of dosing in the TARGET-D 201 Phase 2 registration-directed trial for VS-7375. While these are material clinical developments for a biopharmaceutical company that would affect investor assessment of pipeline value and regulatory prospects, they do not fit neatly into the standard 8-K event taxonomy (not earnings, M\u0026A, impairment, litigation, or other defined categories). This is classified as other_material because clinical trial progress and drug development milestones are significant to investors but lack a dedicated event type.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-17T12:53:14.578943+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":8063,"accession_number":"0001104659-26-074915","item_number":"7.01","item_title":"Regulation FD Disclosure","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.45,"reasoning":"The disclosure announces \"positive updated results\" from the RAMP 205 clinical trial evaluating avutometinib plus defactinib in combination with chemotherapy for metastatic pancreatic cancer. While this is a clinical trial result rather than financial earnings, it is material to a biopharmaceutical company's valuation and would significantly affect investor assessment of pipeline value and regulatory prospects. However, the taxonomy's \"earnings_release\" category is narrowly defined as \"quarterly or annual financial results,\" which this is not—it is a clinical milestone. This disclosure may be better classified as \"other_material\" since it represents a material clinical development event that does not fit the specific categories provided.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-17T12:53:14.578943+00:00","company_name":"Verastem, Inc.","ticker":"VSTM","filing_date":"2026-06-17"},{"id":8064,"accession_number":"0001104659-26-074915","item_number":"8.01","item_title":"Other Events","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"The disclosure announces positive updated clinical trial results from the RAMP 205 Phase 1b/2a trial (86% overall survival rate at 6 months, 68% progression-free survival rate, 52% objective response rate) and the initiation of dosing in the TARGET-D 201 Phase 2 registration-directed trial for VS-7375. While these are material clinical developments for a biopharmaceutical company that would affect investor assessment of pipeline value and regulatory prospects, they do not fit neatly into the standard 8-K event taxonomy (not earnings, M\u0026A, impairment, litigation, or other defined categories). This is classified as other_material because clinical trial progress and drug development milestones are significant to investors but lack a dedicated event type.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-17T12:53:14.578943+00:00","company_name":"Verastem, Inc.","ticker":"VSTM","filing_date":"2026-06-17"}]}